Giannini EG, Pieri G, Labanca S, et al. Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma. Dig liver disease. 2022;54:1215–21.
Lleo A, Wang Guoqing, Gershwin ME et al. Primary biliary cholangitis. Lancet. 2020;396:1915–26.
Han E, Jo SJ, Lee H, et al. Clinical relevance of combined anti-mitochondrial M2 testing in primary biliary cirrhosis. Journal of Clinical Chemistry. 2017;464:113–7.
Dahlqvist G, Gaouar F, Carrat F, et al. Large-scale characterization study of patients with unidentified primary biliary cholangitis who have antimitochondrial antibodies. Hepatology. 2017;65:152–63.
Granito A, Muratori P, Quarneti C, et al. Antinuclear antibodies as secondary markers in primary biliary cirrhosis. Experts revise molecular diagnostics. 2012;12:65–74.
Zeng Na, Duan Wen, Chen S, et al. Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis. Liver Int 2019;13:788–99.
Lu Ming, Zhou Y, Haller IV, et al. Primary biliary cholangitis has increased prevalence and reduced mortality with treatment. Clinical Gastroenterology and Hepatology. 2018;16:1342-1350.e1.
Lindor KD, Bowlus CL, Boyer J, et al. Primary biliary cholangitis: American Association for the Study of Liver Diseases 2018 practice guideline. Hepatology. 2019;69:394–419.
Goel A, Kim WR. Natural history of primary biliary cholangitis in the ursodeoxycholic acid era: role of scoring systems. Clinical liver disease. 2018;22:563–78.
John BV, Khakoo NS, Schwartz KB, et al. Ursodeoxycholic acid response is associated with reduced mortality in primary biliary cholangitis in compensated cirrhosis. Am J Gastroenterol. 2021;116:1913–23.
Yoon CI, Kim D, Ahn SG, et al. A high neutrophil-to-lymphocyte ratio induced by radiation therapy is a negative prognostic factor in breast cancer patients. Cancer (Basel). 2020;12.
Flores-Bustamante A, Hernandez-Regino L, Castillejos-Lopez MD, et al. Changes in the neutrophil-to-lymphocyte ratio as a predictor of outcome in pediatric patients with central nervous system tumors undergoing surgical resection. Cancer biomarkers. 2022;33:291–8.
Toya K, Tomimaru Y, Kobayashi S, et al. Preoperative neutrophil-to-lymphocyte ratio predicts pancreatic fistula healing time after distal pancreatectomy. Ann gastrointestinal surgeon. 2022;6:169–75.
Lin L, Pu Ming, Jiang X, et al. Can the neutrophil-to-lymphocyte ratio predict 1-year mortality in patients with primary biliary cholangitis? Validation of results from a cohort retrospective study. BMJ Open. 2017;7:e015304.
Dong FC, Tan Wenwen, Wang Xiaobo, et al. The neutrophil-to-lymphocyte ratio represents a marker of systemic inflammation and is associated with 90-day mortality in noncirrhotic chronic severe hepatitis. J Dig Dis. 2022;23:587–96.
Shavakhi M, Nourigheimasi S, Dioso E, et al. Prognostic role of neutrophil-to-lymphocyte ratio in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Journal of Gastroenterology and Hepatology. 2022;2022:1554079.
Cusi K, Isaacs S, Barb D, et al. American Society of Clinical Endocrinology Clinical Practice Guidelines for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrine Clinical Settings: Co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocrinology Practice. 2022;28:528–62.
European Association for the Study of the Liver, electronic address eee, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Diagnosis and treatment of patients with primary biliary cholangitis. J Hepatol. 2017;67:145–72.
Yang Y, Sun G, Diao S, et al. Diagnostic performance of neutrophil-to-lymphocyte ratio and lymphocyte-to-monocyte ratio in acute ischemic stroke caused by cervical and cranial artery dissection J Clinical Laboratory Analysis. 2020;34:e23515.
Dunn GP, LJ Sr., Schreiber RD. Immunobiology of cancer immunosurveillance and immunoediting. immunity. 2004;21:137-48.
Li Y, Zhao Y, Feng L, et al. Comparison of the prognostic value of inflammatory markers in patients with acute pancreatitis: a retrospective cohort study. BMJ Open. 2017;7:e013206.
Dong Cheng, Wang Zhiming, Chen Siyi. Neutrophil-to-lymphocyte ratio predicts mortality and major adverse cardiac events in acute coronary syndrome: a systematic review and meta-analysis. Clinical Biochemistry. 2018;52:131–6.
Bannerga A, Alasaradnam RP. Neutrophil-to-lymphocyte ratio and albumin-bilirubin grade in hepatocellular carcinoma: a systematic review. World Journal of Gastroenterology. 2020;26:5022–49.
Xue TC, Zhang L, Xie XY, et al. Prognostic significance of the neutrophil-to-lymphocyte ratio in primary liver cancer: a meta-analysis. PLoS One. 2014;9:e96072.
Zhao Z, Liu J, Wang J, et al. Platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) are associated with chronic hepatitis B virus (HBV) infection. International Immunopharmacology. 2017;51:1–8.
Guo Mingtai, Hu Taihua, Lu Sheng’en, etc. Neutrophil-to-lymphocyte ratio as a predictor of response to peginterferon plus ribavirin in the treatment of chronic hepatitis C. Dis mark. 2014;2014:462958.
Abdel-Razik A, Mousa N, Shabana W, et al. A new model using mean platelet volume and neutrophil-to-lymphocyte ratio as markers of nonalcoholic steatohepatitis in patients with NAFLD: a multicenter study. European Journal of Gastroenterology and Hepatology. 2016;28:e1-9.
Yoo JJ, Cho EJ, Lee B, et al. Prognostic value of the biochemical response model in primary biliary cholangitis and the additive role of the neutrophil to lymphocyte ratio. Intestines and liver. 2018;12:714–21.
Weber GJ, Hirschfeld GM. 2016 Primary Biliary Cholangitis: HD PBC: Biology, Models, and Treatment Advances. Nat Rev Gastroenterol Hepatol. 2017;14:76–8.
Liaskou E, Hirschfield MD, Gershwin ME. Mechanisms of tissue damage in autoimmune liver disease. Serum Immunopathology. 2014;36:553–68.
Isse K, Harada K, Nakanuma Y. IL-8 expression by bile duct epithelial cells correlates with neutrophil infiltration and reactive bile ducts. Liver Int 2007;27:672–80.
Cao Hong, Zhu Bo, Qu Yong, etc. Abnormal expression of ERα in cholangiocytes in patients with primary biliary cholangitis mediates intrahepatic bile duct inflammation. Pre-Immunology. 2019;10:2815.
Zimmermann HW, Seidler S, Gassler N, et al. Interleukin-8 is activated in patients with chronic liver disease and is associated with hepatic macrophage accumulation in human liver fibrosis. “PLOS One.” 2011;6:e21381.
Tsuneyama K, Baba H, Morimoto Y, et al. Pathological characteristics and immunopathological mechanisms of primary biliary cholangitis. Journal of Medical Research 2017;64:7–13.
Lleo A, Invernizzi P, Mackay IR, et al. Pathogenesis of primary biliary cirrhosis. World Journal of Gastroenterology. 2008;14:3328–37.
Yu Ke, Li Ping, Xu Tao, et al. Decreased CD4(+) Th1 cell infiltration indicates that primary biliary cholangitis responds well to ursodeoxycholic acid (UDCA). Pathology Research Practice. 2021;217:153291.
Tang Li, Zhong Rui, He Xiao, et al. Evidence for a correlation between IgG antimitochondrial antibodies and the biochemical response to ursodeoxycholic acid in the treatment of primary biliary cholangitis. J Gastroenterology Hepatology. 2017;32:659–66.
Wen Min, Menrui, Fan X, et al. Patients with primary biliary cholangitis with features of autoimmune hepatitis respond more poorly to ursodeoxycholic acid. Dig Dis. 2021;39:366–74.
Carbone M, Mells GF, Pells G, et al. Gender and age are determinants of clinical phenotype and response to ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology. 2013;144:560-569.e7 Test e13–4.
Muratori P, Granito A, Pappas G, et al. Serological characteristics of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol. 2009;104:1420–5.
Quarneti C, Muratori P, Lalanne C, et al. Fatigue and pruritus present in the more aggressive subtype of primary biliary cirrhosis. Liver Int 2015;35:636–41.
Jones DE, Al-Rifai A, Frith J, et al. Independent effects of fatigue and UDCA treatment on mortality in primary biliary cirrhosis: 9-year follow-up results. J liver alcohol. 2010;53:911–7.
Raj A, Shah KVK. Current and potential treatments for primary biliary cholangitis. Lancet Gastroenterol Liver. 2019;5.